4//SEC Filing
LIN SUE-JEAN 4
Accession 0001867788-25-000005
CIK 0001787306other
Filed
Nov 24, 7:00 PM ET
Accepted
Nov 25, 6:27 PM ET
Size
12.6 KB
Accession
0001867788-25-000005
Insider Transaction Report
Form 4
LIN SUE-JEAN
Director
Transactions
- Exercise/Conversion
Common Stock
2025-11-24$8.63/sh+18,052$155,789→ 44,787 total - Sale
Common Stock
2025-11-24$30.78/sh−25,272$777,956→ 26,735 total - Exercise/Conversion
Stock Option (right to buy)
2025-11-24−7,220→ 5,000 totalExercise: $7.51Exp: 2033-05-31→ Common Stock (7,220 underlying) - Exercise/Conversion
Common Stock
2025-11-24$7.51/sh+7,220$54,222→ 52,007 total - Exercise/Conversion
Stock Option (right to buy)
2025-11-24−18,052→ 9,000 totalExercise: $8.63Exp: 2034-06-14→ Common Stock (18,052 underlying)
Footnotes (3)
- [F1]The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.
- [F2]The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
- [F3]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $30.56 to $30.91, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Documents
Issuer
Arcutis Biotherapeutics, Inc.
CIK 0001787306
Entity typeother
Related Parties
1- filerCIK 0001867788
Filing Metadata
- Form type
- 4
- Filed
- Nov 24, 7:00 PM ET
- Accepted
- Nov 25, 6:27 PM ET
- Size
- 12.6 KB